甲基泽伊拉斯特尔通过PERK/eIF2α/ATF4/CHOP介导的细胞亡来缓解髓性白血病
Xue Li1, Xianchao He1, Leyan Zhang2
1Medical School of Guizhou University, Guiyang, China.
Translational cancer research
|January 9, 2026
概括
甲基泽伊拉斯特拉 (DML) 通过PERK/eIF2α/ATF4/CHOP通路诱导亡,有效地对抗髓性白血病. 这种天然化合物显示出作为一种新的治疗药物用于血液恶性瘤的承诺.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓性白血病需要新的治疗药物.
- 甲基泽伊拉斯特拉 (DML) 是一种天然的类化合物,具有广泛的抗瘤活性.
- 骨髓性白血病中DML的特定作用和机制仍未得到充分研究.
研究的目的:
- 为了研究DML对髓性白血病细胞增殖和亡的影响.
- 阐明DML在髓性白血病中的作用的潜在分子机制.
主要方法:
- 细胞活力测试 (CCK-8) 和流细胞计被用于评估增殖,细胞循环和细胞亡.
- 测量了内质网膜 (ER) 压力标志物,包括细胞内,活性氧物种 (ROS) 和腺三酸盐 (ATP) 水平.
- 转录组测序,KEGG通路分析,shRNA干扰和西部抹杀阐明了DML诱导的信号通路.
- 在活体中,有效性使用髓性白血病异种移植小鼠模型进行了评估.
主要成果:
- DML显著降低了髓性白血病细胞活力,并诱导了G0/G1阶段的停止和亡.
- DML引发了内等质网膜 (ER) 压力,通过增加细胞内,ROS和未折叠的蛋白质积累以及ATP枯竭来证明这一点.
- 转录组分析显示,DML激活了PERK/eIF2α/ATF4/CHOP信号轴,导致未折叠的蛋白质反应 (UPR) 和随后的亡.
- 在体内研究表明DML的抗白血病活性,在异种移植模型中延长存活时间.
结论:
- 在骨髓性白血病细胞中,DML会诱导细胞亡.
- 该机制涉及PERK/eIF2α/ATF4/CHOP信号通路的激活.
- 后期的ER压力和随后的UPR是DML的亡效应的关键调解者.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...